A COVID‑19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID‑19). Although no vaccine has completed clinical trials, there are multiple efforts in progress to develop such a vaccine. In February 2020, the World Health Organization (WHO) said it did not expect a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus, to become available in less than 18 months.[1] Previous attempts to develop a vaccine against the coronavirus diseases SARS and MERS established considerable knowledge about the structure and function of coronaviruses – which accelerated rapid development during early 2020 of varied technology platforms for a COVID‑19 vaccine – but all the previous coronavirus vaccine candidates failed in early-stage clinical trials, with none being advanced to licensing.[2]
The Coalition for Epidemic Preparedness Innovations (CEPI) – which is organizing a US$2 billion worldwide fund for rapid investment and development of vaccine candidates[3] – indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021.[4] On 4 May 2020, the WHO organized a telethon which received US$8.1 billion in pledges from forty countries to support rapid development of vaccines to prevent COVID‑19 infections.[5] At the same time, the WHO also announced deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching Phase II-III clinical trials.[6]
In July 2020, 205 vaccine candidates were in development, with 19 in human testing: one as a Phase II-III interventional trial using thousands of participants, two in Phase II efficacy and dose-testing studies, four in Phase I–II safety and efficacy trials, and twelve in Phase I trials.[7][8][9]
Nice article bro